Introduction
============

Frontotemporal dementia (FTD) represents a group of clinically, neuropathologically and genetically heterogeneous disorders. It is a range of progressive dementia syndromes associated with focal atrophy of the orbitomesial frontal and anterior temporal lobes. And the term frontotemporal lobar degeneration (FTLD) to describe the pathological syndrome.

In 1892, Arnold Pick described a patient with progressive aphasia and lobar atrophy \[[@B1]\]. In 1911, Alois Alzheimer described the histopathological status related to these patients, pointing the absence of senile plaques and neurofibrillary tangles, and the presence of argyrophilic neuronal inclusions (later called "Pick bodies") and swollen cells (later called "Pick cells") at neuropathological examination \[[@B2]\]. However, during the 20th century, these patients with frontotemporal lobar degeneration were generically referred to as patients with dementia, being often diagnosed with Alzheimer disease (AD) \[[@B2]\]. In 1994, two major research groups from Lund and Manchester proposed clinical and neuropathological criteria for the diagnosis of FTD \[[@B3]\]. In 1998, Neary et al \[[@B4]\] reported a consensus on clinical diagnostic criteria of frontotemporal lobar degeneration in the American Academy of Neurology (AAN).

FTD often begins when the patient is in the fifth to seventh decades. Epidemiological studies suggest that FTD is the second most common cause of dementia in individuals younger than 65 and is just less common than Alzheimer's disease (AD) within this age group \[[@B2],[@B5]\]. Of over 65 years old dementia, the incidence of FTD ranks fourth, the top three is Alzheimer's disease, Lewy body dementia and vascular dementia \[[@B5]-[@B7]\]. There do not appear to be any clear gender differences in susceptibility \[[@B8]-[@B11]\]. Among the FTD clinical syndromes, sex distribution appears to vary from one subtype to the next. Several studies report a male predominance in bvFTD and SD, and a female predominance in PNFA \[[@B5],[@B12]\]. There is a wide range in durations of illness (2-20 years) partly reflecting different underlying pathologies.

In the past few years, significant advances have been seen in the etiology, pathogenesis, and genetics, pathology and clinical phenotype of FTD, and many new terminology and classification of FTD have emerged. In this review, recent advances on the different clinical variant phenotypes, neuroimaging, hereditary forms, pathological subtypes and clinicopathological associations of FTD will be discussed.

FTLD clinical presentation: classification and characteristics
==============================================================

Frontotemporal lobar degeneration (FTLD) includes a group of progressive degenerative disorders characterised by progressive behavioural change, executive dysfunction and language difficulties \[[@B13]\]. Unlike AD, behavioral symptoms predominate in the early stages of FTLD. The clinical heterogeneity in familial and sporadic forms of FTD is remarkable, with patients demonstrating variable mixtures of disinhibition, dementia, PSP, CBD, and motor neuron disease \[[@B13],[@B14]\]. Early symptoms are divided among cognitive, behavioral, and sometimes motor abnormalities, reflecting degeneration of the anterior frontal and temporal regions, basal ganglia, and motor neurons \[[@B13],[@B14]\]. FTLD is a powerful model to study emotion, social cognition and language organization in the brain.

Behavioral variant frontotemporal dementia (bvFTD)
==================================================

bvFTD has the highest prevalence amongst the FTD clinical syndromes, accounting for approximately 70% of all FTD cases \[[@B2],[@B5]\]. The onset of bvFTD is typically before the age of 65 years, with an average onset age of 58 years \[[@B12],[@B15]\]. Patients with this clinical variant present with marked changes in personality and behaviour and with relative preservation of the cognitive functions praxis, gnosia and memory \[[@B13],[@B16]\]. Common behavioral deficits include apathy, disinhibition, weight gain, food fetishes, compulsions, euphoria, and an absence of insight into their condition. Poor business decisions and difficulty organizing work tasks are common. Cognitive testing typically reveals spared memory but impaired executive functions \[[@B3],[@B13],[@B17]\]. bvFTD has been associated with symmetrical ventromedial frontal, orbital frontal, and insular atrophy and left anterior cingulate atrophy \[[@B18]\]. Behavioural assessment is at the core of assessment in patients with potential bvFTD and seems to be more sensitive in distinguishing bvFTD from AD than standard cognitive testing. The 'International Behavioral Variant FTD Criteria Consortium' developed international consensus criteria for bvFTD. Subclassifications were made in possible bvFTD defined by clinical criteria, probable bvFTD supported by neuroimaging data, and definite bvFTD confirmation by neuropathological evidence or a pathogenic mutation \[[@B17]\].

Primary progressive aphasia (PPA)
---------------------------------

PPA is a language disorder that involves changes in the ability to speak, read, write and understand what others are saying. It is associated with early temporal lobe atrophy or brain lesions around the lateral fissure. PPA represents a spectrum of selective language disorders and the variant of PPA might provide clues to the underlying pathology \[[@B19]\]. Currently cerebrospinal fluid (CSF) biomarkers have limited ability to identify PPA reliably, which might be explained by the pathological heterogeneity. An indication of lower Aβ1-40 levels or the lower T-tau to Aβ1-42 ratio in FTD, might be useful to distinguish patients from subjects AD and control subjects \[[@B20],[@B21]\]. In 2011, criteria were adopted for the classification of PPA into three clinical subtypes: nonfluent/agrammatic variant PPA (nfvPPA or PNFA), semantic variant PPA (svPPA or SD) and logopenic variant PPA (lvPPA) \[[@B22]\]. The proposal is an important step forward in establishing the consistency of terminology and classification of PPA. The diagnostic recommendations include two steps. First, the patient should meet the basic standard of PPA, which is an initial presentation of significant damage to language and accompanied by limited daily living skills and other cognitive impairment. Second, we need to assess the main language domains, including verbal generation, repeat, and understanding of words and syntax, naming, semantic knowledge and reading/spelling characteristics. Finally, clinical variants will be divided basing on specific speech and language features characteristic of each subtype. Classification can then be further specified as "imaging-supported" if the expected pattern of atrophy is found and "with definite pathology" if pathologic or genetic data are available. Therefore, the new proposal has a clear practical significance.

nfvPPA or PNFA is the second most prevalent presentation of FTLD, accounting for a large 25% \[[@B12]\]. The feature of nfvPPA includes grammatical error making agrammatism and/or laborious speech, but relatively preserved language comprehension. Apraxia of speech (AOS) or orofacial apraxia is frequently accompanying the aphasia \[[@B15]\]. Semantic variant PPA (svPPA) or SD presents in 20--25% of the FTLD patients \[[@B12]\]. svPPA presents a significantly impaired naming ability and word comprehension, while speech production is spared \[[@B22],[@B23]\]. LvPPA or logopenic progressive aphasia \[[@B24]\] is marked by impaired word finding and difficult repetition. lvPPA showes an impaired ability to repeat sentences or phrases, spontaneous speech and a single word extracting when naming. Unlike other FTD subtypes, lvPPA generally does not produce changes in behavior or personality until later stages of the disease. Most people with progressive aphasia maintain the ability to care for themselves, keep up outside interests and, in some instances, remain employed for a few years after onset of the disorder. LPA is mostly associated with a neuropathological diagnosis of AD \[[@B25]\]. Clinical distinction between bvFTD, nfvPPA and svPPA is often complicated for that overlap of the clinical syndromes between them can occur in advanced stages of disease.

FTLD overlaps with other clinical syndrome
------------------------------------------

The subcortical nuclei and motor systems are involves in FTLD variants. Motor neuron dysfunction (MND) has been described in 40% of the FTLD patients, referred to as FTLD-MND. The common comorbidity of Amyotrophic lateral sclerosis (ALS) with behavior abnormality, cognitive impairment or dementia has been noticed \[[@B26],[@B27]\]. FTLD may precede, follow or coincide with the onset of motor symptoms \[[@B28]\]. Other disorders are closely related to FTLD, including progressive supranuclear palsy (PSP) syndromes, corticobasal syndrome (CBS), FTD with parkinsonism (FTDP) and argyrophilic grain disease (AGD). PSP and CBS are two common atypical parkinsonian syndromes demonstrating cognitive and behaviour disorders that overlap with FTD. Of them, behavioral and cognitive dysfunction promotes the development of dementia. And extrapyramidal system symptoms present as bradykinesia, abnormal posture, rigidity, but tremor uncommon. The co-occurrence of AGD in ALS is not uncommon, and comparable with that in a number of diseases belonging to the tauopathies or α-synucleinopathies \[[@B29]\]. Motion system damage presents as muscle atrophy. FTDP-17 showing genetic linkage to chromosome 17, presents with a clinical syndrome of autosomal dominant disinhibition, dementia, parkinsonism, and amyotrophy \[[@B30]\]. The clinical picture resembles bvFTD, while cognitive deficits include anterograde memory dysfunction in an early stage, later the deterioration of visuospatial function, orientation and global memory are gradually presented. Motor signs typically include the symmetrical bradykinesia without resting tremor, in combination with axial rigidity and postural instability. The early clinical presentation of AGD is similar to AD but it is less aggressive, with patients maintain mild cognitive impairment (MCI) for many years \[[@B31]\].

Neuroimaging in FTLD
====================

Neuroimaging plays a critical role in diagnosis of FTD. Neuroimaging investigations can reliably differentiate FTLD subtypes from other dementias, and can help clinical diagnostics based on neuropsychiatric symptoms. Different clinical variatents have different forms of brain atrophy, which can be used for some important clues for early clinical differential diagnosis. DTI can detect white matter damage, different subtypes of white matter injury also help clinical early differential diagnosis of clinical subtypes of FTLD \[[@B32]\]. Functional neuroimaging techniques, such as \[^99^mTc\]-hexamethylpropyleneamine oxime single-photon emission computed tomography (SPECT) \[[@B33]\] or \[^18^ F\]-fluorodeoxyglucose (FDG)-PET are increasingly being used to help with the diagnosis of FTLD \[[@B34]\]. Arterial spin labeling imaging (ASL) like FDG-PET can be used for showing the hypometabolism in brain regions. Hypometabolism on FDG-PET is detected consistently and reliably in frontal brain regions in patients with bvFTD compared with those with AD, who show posterior cingulate hypometabolism early in the disease process \[[@B34]\]. However, in patients showing clear brain atrophy on structural MRI, little additional diagnostic benefit is gained by doing a PET scan, because focal atrophy is a positive predictive marker of FTD. The imaging presentation of nfvPPA indicates that predominant left posterior fronto-insular atrophy on MRI or predominant left posterior fronto-insular hypoperfusion or hypometabolism on SPECT or PET. Imaging-supported svPPA show predominant anterior temporal lobe atrophy and/or these brain regions hypoperfusion or hypometabolism on SPECT or PET. The imaging of lvPPA must show at least one of predominant left posterior perisylvian or parietal atrophy on MRI and/or hypoperfusion or hypometabolism on SPECT or PET \[[@B22],[@B25],[@B35]-[@B37]\].

Future in FTLD are very similar to imaging in AD--early detection, molecular diagnosis, monitor disease progression and validate and implement disease modifying therapies. Specific anatomic patterns in FTLD, and an amyloid-PET neuroimaging, which uses the amyloid-β-detecting ^11^C-Pittsburgh compound B, has shown promising results in discriminating or rule-out atypical AD and FTD cases \[[@B38],[@B39]\] particularly those presenting with language deficits rather than behavioural changes. Micro PET with ^18^ F-THK523 in Tau transgenic mice have been reported \[[@B40]\]. Tau specific imaging scanner that uses the ^18^ F-THK523 may be a promising technique coming soon in future \[[@B40]\].

FTLD Neuropathology and cliniconeuropathological correlations
=============================================================

Neuropathology
--------------

The subtypes of underlying pathological changes in patients with FTD are classified on the basis of the pattern of protein deposition, and are referred to collectively as frontotemporal lobar degeneration. Under a microscope, common pathologic changes of FTLD are atrophy brain region presenting neuronal loss, spongy change and gliosis in cortices of atrophied frontal and temporal lobes \[[@B41],[@B42]\].

FTD have identified novel genetic defects and a chromosomal locus in hereditary forms of FTLD, as well as novel clinicneuropathological associations. Immunohistochemistry allows subcategorization of these disorders into specific proteinopathies based on the major constituent of the inclusions.

\(1\) **FTLD-tau**: One subtype is presented as neurons  and glial cells containing inclusions of  hyperphosphorylated tau protein, referred to as  FTLD-tau \[[@B43]\]. Tau pathology was associated with  FTD with parkinsonism, PSP syndromes \[[@B44]\], CBS  \[[@B45]\] and AGD \[[@B31]\].

\(2\) **FTLD-Ubiquitin or FTLD-U**: Over 50% of the  FTLD patients presented with tau-negative  ubiquitin staining inclusions, referred to as FTLD- Ubiquitin or FTLD-U \[[@B46]\]. In 80--95% of this  group, inclusions were found to be composed of  transactive response (TAR) DNA-binding protein  43 kDa (TDP-43) \[[@B47]-[@B49]\], referred to as FTLD-TDP  \[[@B50]\], or TDP-43-negative FTLD-U cases having  inclusions of fusedin-sarcoma protein (FUS), referred  to as FTLD-FUS \[[@B43],[@B49],[@B51],[@B52]\]. However, in a small  number of FTLD-U patients, the inclusion protein  remains unclear. This group is referred to as FTLD- ubiquitin proteasome system (FTLD-UPS) \[[@B46],[@B53]\].

\(3\) Dementia lacking distinctive histopathology  (DLDH) \[[@B54],[@B55]\].

\(4\) Other rare types: dementia with basophilic  inclusion body, neuronal intermediate filament  inclusion disease \[[@B52]\].

Association between pathology and clinical phenotype
----------------------------------------------------

Associations were noted between the clinical FTLD subtypes and underlying proteinopathies, but a strict one to one relationship is lacking. bvFTD is mostly associated with FTLD-TDP43, some cases are also correlated with FTLD-tau (PiD subtype). An FTLD-FUS proteinopathy is invariantly associated with a clinical diagnosis of bvFTD, either with or without the signs of MND. Microscopic assessment of nfaPPA at autopsy often reveals FTLD associated with a tauopathy (FTLD-tau). nfaPPA is commonly associated with tau pathology, especially when AOS or orofacial apraxia is present. In most cases, the pathology underlying nfaPPA was mixed, including FTLD-tau and FTLD-TDP43, but with a predominance of FTLD-tau pathology. SvPPA is, in most cases, linked with TDP-43-immunoreactive pathology, although tau pathology is sometimes observed. Some patients with predominantly right temporal lobe atrophy (RTLA) are usually diagnosed clinically with either bvFTD or svPPA \[[@B56]\]. It has been suggested that patients with bvFTD and RTLA have FTLD-tau pathology, whereas patients with svPPA and RTLA have FTLD-TDP43 pathology \[[@B56]\]. svPPA patients who often present with acalculia is associated with FTLD-tau \[[@B57]\]. LvPA is predominantly associated with AD pathology. Many patients with lvPPA often have underlying AD pathology \[[@B58]-[@B60]\]. CSF tau:amyloid-β ratio \[[@B37]\] and PiB PET imaging \[[@B25]\] studies can be helpful in the identification of patients who are more likely to have lvPPA than nfaPPA. A recent study showed that 93% of patients with lvPPA on amyloid PET imaging was found PiB positive, but svPPA only 9%, nfvPPA is 13%, which suggests that there is some common pathological features between lvPPA and AD \[[@B59]\].

Tau pathology was also associated with FTLD with parkinsonism, PSP, CBD, AGD and Pick bodies (PiD) \[[@B30],[@B44],[@B61]\]. Similarly, TDP-43 and FUS proteinopathies are also commonly found in MND with or without FTLD \[[@B52]\]. Although these are relatively strong associations, they are not absolute, and it is currently not possible to predict with certainty the underlying pathology of specific FTLD syndromes.

Extrapyramidal system symptoms accompanied with apraxia indicates the presence of CBS, which mostly attributes to Tau disease. While dementia with FTLD-MND syndrome mostly attributes to TDP-43 pathology \[[@B15],[@B45],[@B57]\]. These suggest that it is contributing to therapeutic strategy for FTLD through elucidating the relationship between pathological and clinical presentation.

Molecular genetics
==================

Approximately 40% of patients with FTD have a family history \[[@B8]\]. bvFTD is the most prominent subtype with family history, especially when concomitant symptoms of MND are present (60%), while SvPPA appeared to be the least hereditary FTLD subtype (\<20%) \[[@B62]\]. Molecular genetic studies have identified several common (*MAPT, GRN*) and rare (*VCP, CHMP2B, TARDBP, FUS*) genetic factors in hereditary FTLD over recent years. In 1998 microtubule associated protein tau (MAPT) gene was found, which located on chromosome 17q21.32, in which 13% of the cases is FTDP-17, those who have parkinson-like symptoms \[[@B63]\]. In 2004, the gene encoding valosin-containing protein (VCP) gene was found, located on chromosome 9p13.3, which is associated with the genes that cause FTLD in association with inclusion body myopathy and Paget's disease \[[@B64],[@B65]\]. In 2005, the charged multivesicular body protein 2B (CHMP2B, also known as chromatin-modifying protein 2B) gene mutations, located on chromosome 3p11.2, was discovered in a large Danish cohort with familial FTLD \[[@B66],[@B67]\]. In 2006, a mutated gene located on chromosome 17q21.31 are identified as the granule protein precursor (PGRN), only 1.7 M nucleotide away from the MAPT \[[@B68],[@B69]\]. Approximately 10% of patients with FTLD is associated with this gene. In 2011, chromosome 9 open reading frame 72 (C9ORF72) gene was newly identified in FTLD \[[@B70],[@B71]\].

Overall, patients with mutations in *GRN, MAPT* and *C9ORF72* together account for at least 17% of total FTD cases \[[@B53],[@B72]\]. Summed *C9ORF72, GRN* and *MAPT* mutation frequencies were 32-40% \[[@B70],[@B73]\]. Mutations in *VCP* and *CHMP2B* are rare, each explaining less than 1% of the familial FTLD.

The MAPT gene mutations often lead to FTLD-Tau pathological changes. The Both *PGRN* and *C9ORF72* mutations can cause FTLD-TDP-43. The symmetry frontal lobe atrophy in bvFTD patients is associated with *C9ORF72* and *MAPT* gene mutations, whereas the asymmetry of frontal lobe atrophy in bvFTD patients is associated with *PGRN* gene mutations \[[@B74]\]. The large hexanucleotide repeat expansion located within the non-coding portion of *C9ORF72* is the cause of chromosome 9-linked ALS and FTLD \[[@B70]\]. These suggest that specific gene mutations may affect the patterns of neuroanatomic injury in the development of frontal lobar atrophy.

*C9ORF72* is expressed as three major transcripts and the expanded G4C2 repeat is located in the proximal regulatory region of *C9ORF72*\[[@B70],[@B73]\], upstream of one and in the first intron of the two other transcripts. Repeat expansion results in near complete loss of expression of the major gene transcripts. The pathogenic expansion was non-penetrant in individuals younger than 35 years, 50% penetrant by 58 years, and almost fully penetrant by 80 years. In normal population, the size of the G4C2 repeat ranges from 3 to 25 units, which is expanded to at least 60 units in FTLD patients \[[@B70],[@B71],[@B73]\].

The clinical phenotype of *C9ORF72* mutation often presents as bvFTD or ALS or FTD co-morbidities ALS. In patients with bvFTD, *C9ORF72* mutation is more common than *MAPT* or *PGRN*. Anxiety or agitation, and memory dysfunction (often episodic memory) is a common clinical feature. Those cases underlines that the hexanucleotide repeat expansion in chromosome 9 could be also associated with early onset psychiatric presentations \[[@B75]\]. Overexpressed p-62 inclusion body lesions in the cerebellum is one of pathological features \[[@B76]\]. Neuroimaging presents as the symmetrical frontal and/or temporal lobe atrophy, and parietal, occipital and cerebellar atrophy can also appear. Therefore, *C9ORF72* mutation is not only associated with cortical anatomic site but also with subcortical structures. However, it is unclear for the exact mechanism of action of this "repeat amplification *C9ORF72* gene".

The clinical and pathological heterogeneity in FTLD causes a challenge for diagnosis of FTLD. A helpful supplement for clinical evaluation using genetics and biological markers testing can significantly improve the forecast of potential histopathology *in vivo*. We summarize clinical phenotypes, molecular pathological and genetic spectrum in FTLD in Table [1](#T1){ref-type="table"}. And the profile of main genes mutations and its possible disease mechanisms in FTLD is shown in Table [2](#T2){ref-type="table"}.

###### 

**Clinical phenotypes, pathological and molecular genetic spectrum in FTLD**\[[@B13],[@B19],[@B22],[@B35],[@B72],[@B77],[@B78]\]

          **Core clinical feature**                       **Praxiological obstacle**                                      **Logopathy**                          **Extrapyramidal symptoms + praxiological obstacle**               **Dyskinesia + praxiological obstacle**                                                                                              
  ------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------ ------------------------------------ -------------------------
            **Clinical syndrome**             Behavioral variant Frontotemporal dementia (bvFTD)                Primary progressive aphasia(PPA)                            Corticobasal degeneration (CBD)                           progressive supranuclear palsy (PSP)                              FTD-MND/ALS                                                      
                                                                                                            nonfluent/agrammatic variant PPA (nfvPPA)                         Semantics variation (svPPA)                                logopenic variant PPA (lvPPA)                                                                                                                
   **Brain morphologically affected parts**           Prefrontal lobe and temporal lobe                        Left posterior frontal lobe, insula                          The front/ventral temporal lobe              left posterior superior temporal lobe and medial parietal lobe   Frontal and temporal lobe, Basal ganglia      Basal ganglia and brainstem       Cortex and motor neuron
     **Biochemistry and Neuropathology**           FTLD-Tau (Pick type, 3R-tau) FTLD-TDP43         FTLD-Tau more than FTLD-TDP43, AD like pathological visible   Most belongs to FTLD-TDP43; AD like pathological rare          AD-like pathological common; FTLD-TDP43 visible              FTLD-Tau (CBD type,4R-tau) common       FTLD-Tau (PSP type, 4R-tau) common    FTLD-TDP43, FTLD-FUS
      **Causative and Associated Genes**                          *C9ORF72*                                                  *PGRN,*                                                   *C9ORF72*                                                                                                           *PGRN*                                  *MAPT*                        *C9ORF72*
                    *PGRN*                                        *C9ORF72*                                                  *PGRN*                                                                                                                  *MAPT*                                                *PGRN*                                  *FUS*                 
                    *MAPT*                                          *MAPT*                                                   *MAPT*                                                     *PGRN*                                                     *C9ORF72*                                             *C9ORF72*                                 *VCP*                 
                    *VCP*                                           *VCP*                                                     *VCP*                                                                                                                  *VCP*                                                 *VCP*                                                         
                                                                   *CHMP2B*                                                 *CHMP2B*                                                   *CHMP2B*                                                                                                           *CHMP2B*                                *CHMP2B*                            

Note: 3R tau: three microtubulebinding repeats; 4R tau:four microtubule-binding repeats.

###### 

The profile of main genes mutation and its possible disease mechanisms in FTLD

                                                 **Gene symbol**                                                                                                                                                                                     ***MAPT***                                                                                                                                                                                                                          ***C9ORF72***                                                                                                                                                         ***PGRN***                                                                                                                                 ***VCP***                                                                                                                                    ***CHMP2B***
  ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
                                                       *.*                                                                                                                       *● MAPT*gives rise to six isoforms: three isoforms containing three amino-acid repeats (3R), and three isoforms with four repeats (4R) \[[@B79]\].                                                                                      *●*expressed as three major transcripts, the expanded G4C2 repeat is located in the proximal regulatory region of *C9ORF72*\[[@B70],[@B73]\].                                       *●*encodes progranulin, a ubiquitously expressed growth factor precursor consisting of 7.5 granulin peptides.                     *●*Encodes a ubiquitously expressed member of a family of ATPases associated with a wide range of cellular functions \[[@B85]\].    *●*Encodes a component of the heteromeric ESCRT-III complex with functions in the endosomal-lysosomal and the autophagic protein degradation pathway.
                            **Functions and possible role in the disease mechanism**                             *●* Mutations result in a change in ratio of 3R to 4R tau isoforms. Mutations affect the normal function of the tau protein to stabilise microtubules, increase the tendency of tau to form neurotoxic aggregates and disturb neuronal plasticity and axonal transport \[[@B80]\].   *●*Repeat expansion results in near complete loss of the major gene transcripts. And accumulation of transcripts harboring the expanded G4C2 repeat in nuclear RNA foci \[[@B70]\].   *●*a wide range of biological processes such as inflammation and wound repair, or in pathological conditions including tumorigenesis \[[@B82]\].          *●*mutations reside at the interface between the D1 ATPase and the N-domain of the CDC48-like protein \[[@B85]\].           *●*Expressed in neurons of all major brain regions. It is critical for development, sexual differentiation \[[@B88]\] and neuronal survival \[[@B89]\].
   *●*G4C2 repeat leads to neuronal cytoplasmic inclusions throughout theentire cortical thickness \[[@B81]\].                                                                                            *●*Neurotrophic function involved in neuronal survival and neurite outgrowth \[[@B83],[@B84]\].                                                                                                                                *●*mutations disturb ubiquitin-proteasome mediated protein degradation, autophagy, or both \[[@B86],[@B87]\].                                                                 *●*Mutations affect the C-terminal end of the protein due to aberrant splicing \[[@B78]\].                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *●*unidentified mechanisms exist.                                                                                                                                                                                                                                                                                                                                                                                                                                              
                    **Estimated mutation frequency \[**\[[@B69],[@B72],[@B79],[@B81],[@B90]\]                                                                                                                                                          0-50%                                                                                                                                                                                                                                14-48%                                                                                                                                                               3--26%                                                                                                                                      \<1%                                                                                                                                          \<1%

Conclusion
==========

In this review, we have systematically updated current understanding on clinical, genetic, neuropathological, and neuroimaging perspectives of FTD. This review aims to arouse awareness of FTD among clinicians, in particular when the overlapping clinical and neuroimaging characteristic features among dementia and different subtypes of FTD remain great challenges for clinicians. Identification of biomarkers for clinical diagnosis and differentiation FTD from other dementia is warranted for future studies. Gene diagnosis test should be considered for familial cases suspected with FTD in clinic practice. Longitudinal clinicopathological correlation studies will further elucidate the network functions of human brain in this complex disorder with behaviour, speech and motor abnormality. With further understanding of the genetics, clinical and neuropathological basis of FTD, we can visualise that FTD will be further clinically defined. And new consensus will be developed for better guidance in clinical practice.
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